Trials Sponsors Conditions Drugs Pricing

Conditions

Fibromyalgia

Keywords

Chronic Pain, NK cells, Lymphocytes, Mu Opioid Receptor

Outcome Measures

Primary Outcomes (1)

Identification of percentage of Mu-positive NK cells as predictive markers of pain in suffering patients
Peripheral blood of pain suffering patients who have entered a neurorehabilitation program will be investigated to confirm the modulation of the percentage of Mu-positive NK cells and to evaluate if they could be eligible as predictive markers of chronic pain by correlating it to the level of pain calculated with Numeric Pain Rating Scale.
3 weeks

Study Arms (2)

healthy subjects

subjects with NRS\<5

patients with cronical pain

patients with NRS\>5

Other: Rehabilitation

Interventions

RehabilitationOther

3-weeks rehabilitation in hospital

patients with cronical pain

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

* Experimental group, patients who have an NRS \>5; * Control group, patients who have an NRS \<5.

You may qualify if:

IRCCS San Raffaele Roma patients who entered the neuro-rehabilitation program, aged 18 years older, able to sign a written informed consent.

You may not qualify if:

Sponsors & Collaborators

IRCCS San Raffaele Roma
Otherlead

Study Sites (1)

IRCCS San Raffaele

Roma, 00163, Italy

RECRUITING

Lucia Gatta, PhDCONTACT+390652253440 lucia.gatta@sanraffaele.it

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral blood samples from patients in EDTA

MeSH Terms

Conditions

FibromyalgiaChronic Pain

Interventions

Rehabilitation

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Aftercare

Central Study Contacts

Lucia Gatta, PhD

CONTACT

+390652253440 lucia.gatta@sanraffaele.it

Lucia Carmela Passacatini, Dr

CONTACT

+390652253778

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 10, 2024

First Posted

June 13, 2024

Study Start

October 3, 2023

Actual (reported)

Primary Completion

July 31, 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

NK-ORB Expression of Mu Receptor on Lymphocytes in Rehabilitation

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

healthy subjects

patients with cronical pain

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

healthy subjects

patients with cronical pain

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations